Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

204 Patient benefit Knowledge about specific risk factors allows earlier diagnosis and treatment of cancer. Project coordinator Dr. Olivia Keiser Institut für Sozial- und Präventivmedizin Universität Bern Finkenhubelweg 11 CH-3012 Bern Phone +41 (0)31 631 35 15 okeiser@ispm.unibe.ch Levi Fabio | Modelling, interpretation and forecasting of cancer mortality in Europe (KFS 02347-08-2009) Duration 01.10.2009 – 01.10.2012 The main objective of this project, which started in 1993, is to maintain and improve the integrated system for analyzing, modelling and interpreting mortality statistics in Europe created by our international collaborative group from the WHO raw mortality database. Over the last two decades, total cancer mortality trends were favourable, although to a variable degree, in all major European countries, including Switzerland. The major determinants of these favourable trends were the decline of lung and other tobacco-related cancers in men, together with the persistent falls in gastric cancer and the recent appreciable falls in colorectal cancer. In women, relevant contributions came from the persistent decline in cervical cancer and the recent falls in breast cancer mortality, particularly in Northern and Western Europe. Detailed analyses were conducted and published on trends for oral and pharyngeal, stomach, biliary tract, testis, Hodgkin’s lymphoma and childhood cancer. There is ample need to monitor cancer mortality in Europe continuously, and the wide diffusion of these statistics can have a substantial impact on prevention and public health. Project coordinator Prof. Dr Fabio Levi Unité d’épidémiologie du cancer et Registres vaudois et neuchâtelois des tumeurs Institut universitaire de médecine sociale et préventive Centre hospitalier universitaire vaudois (CHUV) Chemin des Falaises 1 CH-1011 Lausanne Phone +41 (0)21 314 73 11 fabio.levi@chuv.ch Michel Gisela | Effectiveness of transition to adult care after childhood cancer (KLS 02631-08-2010) Duration: 01.04.2011– 01.04.2014 Despite improving cure rates, two-thirds of childhood cancer survivors experience late effects. Follow-up is thus very important. Whereas follow-up is usually well-organized in paediatric care, transition to adult care has often been lacking in Switzerland. We will study clinic documents and medical records to describe the organization of follow-up for childhood cancer survivors in paediatric care, transition to adult care and the information provided to future carers, parents and patients. Together with information from two questionnaire surveys, organization of follow-up and transition to adult care will be described. This study will help to develop well-organized transition from paediatric to adult care such that long-term followup for childhood cancer survivors can be improved. Project coordinator Dr. Gisela Michel Institut für Sozial- und Präventivmedizin Universität Bern Finkenhubelweg 11 CH-3012 Bern Phone +41 (0)31 631 33 47 michel@ispm.unibe.ch Mullis Primus-Eugen | Risk of cancer and long-term mortality in children treated with growth hormone: Swiss participation in the EU FP7 project “Safety and Appropriateness of Growth Hormone Treatment in Europe (SAGhE)” (KLS 02586-02-2010) Duration: 01.07.2010 – 01.01.2013 Growth hormone (GH) is crucial for height gain. Diseases associated with lack of GH can be treated by GH replacement. For example, this GH replacement therapy can be applied to children that cannot produce their own GH after radiotherapy. Data on the long-term safety of this therapy are lacking. A European study, in which Switzerland is also contributing, will now investigate these open questions. This study aims to identify the long-term impact of GH therapy on adult height, quality of life, cancer incidence and mortality. Medical data will be collected from patient files in the hospitals. Information about quality of life and current health status will be assessed by questionnaires sent to the patients. Insights in cancer incidence and mortality can be obtained by comparing these data with the mortality statistics of the Swiss Federal Statistical Office and the national cancer data bases. The patients may benefit through an optimization of therapy guidelines based on the findings of this study. Project coordinator Prof. Dr. Primus-Eugen Mullis Abteilung pädiatrische Endokrinologie, Diabetologie und Stoffwechsel Universitätsklinik für Kinderheilkunde Inselspital CH-3010 Bern Phone +41 (0)31 632 9552 primus.mullis@insel.ch
Thürlimann Beat | Management of breast cancer in the elderly in Switzerland (KFS 02474-08-2009) Duration: 01.03.2010 – 01.11.201 About 40 % of all breast cancer cases are diagnosed in patients aged 65 or older. Data on the aging population demonstrate an unprecedented expansion of the segment of the population aged ≥ 65 years in the last 20 years. There is an urgent need to understand the factors influencing diagnosis and treatment of breast cancer in the elderly. The aim of this study is to examine the patterns of breast cancer care in elderly patients and to determine predictors for substandard treatment. Methods We will include a subgroup of 2,049 breast cancer patients ≥ 65 years of age from the Swiss Breast Cancer Patterns-of-Care study. Three age subgroups will be studied: the young old (65–74 years), the older old (75–84 years) and the oldest old (85 years and older). Patient, tumour characteristics and treatment adherence with national and international guidelines will be analyzed for each of the age subgroups. Predictors for guideline adherence will be analyzed using multivariate regression analysis, adjusting for known risk factors, type of treatment (surgery, radiotherapy, systemic treatment) and age. The potential impact of non-adherence to guidelines will be studied with appropriate statistical techniques. Potential patient benefit This study is unique in providing very detailed data on the quality of breast cancer care in the elderly. Knowledge about the patterns of breast cancer care in the elderly will be crucial to improving diagnosis and treatment in this growing segment of patients. Project coordinator: Prof. Dr. Beat Thürlimann Brustzentrum Kantonsspital St. Gallen 9007 St. Gallen Phone +41 (0)71 494 10 83 Fax +41 (0)71 494 63 68 beat.thuerlimann@kssg.ch Vounatsou Penelope | Spatio-temporal patterns and forecasting of gender-specific lung and other tobacco-related cancer mortality and morbidity rates in Switzerland (KLS 02393-02-2009) Duration: 01.09.2009 – 01.09.2012 In Switzerland, lung cancer is the first cause of cancer mortality in men and the second in women. Although mortality is declining in men, in women it is steadily increasing. The Federal Office of Public Health (FOPH) launched the National Program Tobacco 2008–2012, aiming to reduce “smoking-related cases of death and disease”. Maps of the geographical patterns and trends of lung and other tobacco-related cancers as well as estimates of the disease burden at different regional scales will be important for the design, implementation and evaluation of the National Program Tobacco. Objectives and goals The main objectives of this research are to: 1) produce smooth maps of gender, age and site-specific patterns of tobacco-related cancer mortality since 1969; 2) produce smooth maps of gender, age and site-specific patterns of lung cancer mortality over time adjusted for non-smoking risk factors to obtain an indirect indicator of space-time patterns of smoking hazards; 3) explore differences in cancer mortality rates between linguistic regions, urbanisation and affluence; and 4) develop models for predictions of tobacco-related cancer mortality by region and gender for 2009–2018 and other models. Methods of investigation We propose to accomplish these objectives by employing and further developing Bayesian Poisson and negative binomial: a) spatio-temporal models for area mortality and incidence data; b) shared component models for a joint spatio-temporal analysis of the tobacco-related cancers; c) age-period-cohort models with spatial and temporal random effects to forecast geographical patterns and trends of mortality and incidence; and d) back-calculation models to estimate incidence from mortality data. Significance This research will contribute smooth maps of gender, age and site-specific patterns of lung and other tobacco-related cancer mortality and morbidity over time. The maps will identify discrepancies in disease burden and assist implementation and evaluation of the National Program Tobacco. This information will be useful for planning purposes, such as for resource allocation and costing of medical supplies for diagnosis and treatment. Project coordinator Dr. Penelope Vounatsou Biostatistics and Computational Sciences Unit Departement für Epidemiologie und Gesundheitswesen Schweizerisches Tropen- und Public-Health-Institut Socinstrasse 57 CH-4051 Basel Phone +41 (0)61 284 81 09 penelope.vounatsou@unibas.ch 205
Page 1 and 2:
Cancer Research in Switzerland A pu
Page 3 and 4:
Cancer Research in Switzerland
Page 5 and 6:
Basic biomedical research 55 Cancer
Page 7 and 8:
policy work and was in charge of de
Page 9 and 10:
The main focus of the research fund
Page 11 and 12:
gramme research funding decreased b
Page 13 and 14:
Table 2 Distribution of funds for i
Page 15 and 16:
Funding patient-centred research Pa
Page 17 and 18:
value was not clearly discernible.
Page 19 and 20:
New organization of the Foundation
Page 21 and 22:
The board of the Foundation Cancer
Page 23 and 24:
The president of the Scientific Com
Page 25 and 26:
Prof. Martin Pruschy, PhD Departmen
Page 27 and 28:
Swartz wants to find out how tumour
Page 29 and 30:
The scientific and medical research
Page 31 and 32:
3. The original order/sequence of t
Page 33 and 34:
As a federation, the Cancer League
Page 35 and 36:
List of funded research projects, i
Page 37 and 38:
Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40:
Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42:
Thurgau Cancer League Biotechnologi
Page 43 and 44:
Weller Michael | 2010: CHF 65,828.-
Page 45 and 46:
manageable funding of individual pr
Page 47 and 48:
enhances breast cancer cell motilit
Page 49 and 50:
Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52:
International Clinical Cancer Resea
Page 53 and 54:
in PHIV were shown for Hodgkin’s
Page 55:
Zucca Emanuele et al. | Internation
Page 58 and 59:
56 “hierarchical structure” of
Page 60 and 61:
58 the attempt should be made to st
Page 62 and 63:
60 Gönczy Pierre | KLS 0202402
Page 64 and 65:
62 Romero Pedro | OCS 020110220
Page 66 and 67:
64 Beermann Friedrich | In vivo scr
Page 68 and 69:
66 Christofori Gerhard | Podoplanin
Page 70 and 71:
68 Frei Christian | The function of
Page 72 and 73:
70 cell, this novel mechanism serve
Page 74 and 75:
72 Results The induction of viral p
Page 76 and 77:
74 Hübscher Ulrich | Repair of oxi
Page 78 and 79:
76 Methods and experimental approac
Page 80 and 81:
78 of cMyc and/or NMyc and demo
Page 82 and 83:
80 In summary, this work improves o
Page 84 and 85:
82 Pruschy Martin | Microtubule int
Page 86 and 87:
84 Renner Christoph | Selective inh
Page 88 and 89:
86 Goal Here we build on these obse
Page 90 and 91:
88 by TDG prevents efficient downst
Page 92 and 93:
90 To address these questions, we a
Page 94 and 95:
92 Translational relevance The resu
Page 96 and 97:
94 Grünberg Jürgen | KFS 025460
Page 98 and 99:
96 Tschan Mario P. | KFS 0248608
Page 100 and 101:
98 Boyman Onur | Preclinical testin
Page 102 and 103:
100 Constam Daniel | Role of activi
Page 104 and 105:
102 this study we will examine the
Page 106 and 107:
104 Janscak Pavel | Study of the ro
Page 108 and 109:
106 Müller Anne | The molecular pa
Page 110 and 111:
108 Radtke Freddy | The role of Not
Page 112 and 113:
110 Schär Primo | DNA repair, epig
Page 114 and 115:
112 In this project we will investi
Page 116 and 117:
114
Page 118 and 119:
116 and Research). Other financial
Page 120 and 121:
118 be totally unaffordable for aca
Page 122 and 123:
120 Clinical research List of compl
Page 124 and 125:
122 Hunger Robert E. | OCS 02262-08
Page 126 and 127:
124 Clinical research Presentation
Page 128 and 129:
126 Benhattar Jean | Identification
Page 130 and 131:
128 Bertoni Francesco | Genome-wide
Page 132 and 133:
130 Interpretation ESA treatment in
Page 134 and 135:
132 Our results could pave the way
Page 136 and 137:
134 new drugs that specifically tar
Page 138 and 139:
136 slides in two different concent
Page 140 and 141:
138 Conclusions A strong network of
Page 142 and 143:
140 tions introduced to ARE motifs
Page 144 and 145:
142 Müller Beatrice U. | The maste
Page 146 and 147:
144 A novel method was developed fo
Page 148 and 149:
146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151:
148 Timmermann Beate | Prospective
Page 152 and 153:
150 recurrence of the disease, we a
Page 154 and 155:
152 Zucca Emanuele | A prospective
Page 156 and 157: 154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159: 156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161: 158 activity at the single cell lev
Page 162 and 163: 160 Our research projects aim at un
Page 164 and 165: 162 Körner Meike | In vitro evalua
Page 166 and 167: 164 Nadal David | Is endemic Burkit
Page 168 and 169: 166 (> 50.000/patient). For their a
Page 170 and 171: 168 Zeller Rolf | Functional analys
Page 172 and 173: 170
Page 174 and 175: 172 area of health services researc
Page 176 and 177: 174 The financing of palliative car
Page 178 and 179: 176 National Strategy for Palliativ
Page 180 and 181: 178 Psychosocial research List of c
Page 182 and 183: 180 Within the patient group, level
Page 184 and 185: 182 Further, the results suggest th
Page 186 and 187: 184 It is in this context that the
Page 188 and 189: 186 Recommendation Female spouses o
Page 190 and 191: 188 Psychosocial research Presentat
Page 192 and 193: 190 rates communication skills rema
Page 195 and 196: Epidemiological research Epidemiolo
Page 197 and 198: data from cancer registries. In the
Page 199 and 200: The importance of cancer registries
Page 201 and 202: Ess Silvia | Patterns of care and s
Page 203 and 204: Epidemiological research List of ap
Page 205: Impact This work will serve as the
show all

Cancer Research in Switzerland - Krebsliga Schweiz

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?